Related Experiment Video
Updated: May 31, 2026
10:33
Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells
Published on: November 18, 2022
Do tocotrienols have potential as neuroprotective dietary factors?
Jan Frank1, Xiao Wei Dawn Chin, Charlotte Schrader
1Institute of Biological Chemistry and Nutrition, University of Hohenheim, Stuttgart, Germany. jan.frank@nutrition-research.de
Ageing Research Reviews
|July 19, 2011
Summary
Tocotrienols (T(3)), a form of vitamin E, show potential for neuroprotection by modulating cell death pathways and inhibiting cholesterol synthesis. Enhancing their bioavailability is key for therapeutic use.
Area of Science:
- Nutritional Science
- Neuroscience
- Biochemistry
Background:
- Tocotrienols (T(3)) are vitamin E compounds with unique biological properties.
- They exhibit antioxidant activity and cholesterol-lowering effects by inhibiting HMG-CoA reductase.
- T(3) also modulate signaling pathways involved in neuronal cell death at low concentrations.
Purpose of the Study:
- To explore the neuroprotective potential of tocotrienols (T(3)).
- To identify molecular targets and mechanisms of T(3) action in neuroprotection.
- To address challenges in T(3) bioavailability for therapeutic applications.
Main Methods:
- Review of existing literature on T(3) biological activities, including in vitro, animal, and human studies.
- Analysis of T(3) molecular targets such as prenyl transferases, kinases, and enzymes involved in inflammation.
- Examination of factors affecting T(3) bioavailability and strategies for enhancement.
Main Results:
- T(3) demonstrate neuroprotective effects through antioxidant and anti-inflammatory actions.
- Micromolar concentrations of T(3) inhibit cholesterol biosynthesis, while nanomolar concentrations modulate neuronal cell death pathways.
- Low bioavailability and rapid excretion of T(3) limit their preventive use, though enhancement strategies exist.
Conclusions:
- Tocotrienols (T(3)) show promise as neuroprotective agents due to their diverse biological activities.
- Further research, including animal models and human trials, is needed to confirm T(3) efficacy in neuroprotection.
- Improving T(3) bioavailability is crucial for realizing their therapeutic potential.
Related Concept Videos
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:15Neurogenesis and Regeneration of Nervous Tissue
In the CNS, neurogenesis, the birth of new neurons from stem cells, is limited to the hippocampus in adults. In other regions of the brain and spinal cord, neurogenesis is almost non-existent due to inhibitory influences from neuroglia, especially oligodendrocytes, and the absence of growth-stimulating cues. The myelin produced by oligodendrocytes in the CNS inhibits neuronal regeneration. Furthermore, astrocytes proliferate rapidly after neuronal damage, forming scar tissue that physically...
01:25Bioactivation and Tissue Toxicity
Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:18Lipids: Dietary Sources and Requirements
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ meats, shellfish,...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.